BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $56
BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $56.
An expert who watches Boston Scientific still thinks it's a good company to own, but thinks it might be worth a bit less money than before. When experts lower their price targets, it's worth noticing what changed—but it doesn't mean the company got worse.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.